Paradigm Biopharma
0 followers
Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.
Org chart
Paul Rennie
Founder & Chairman
Paul Rennie
Collapse
Simon White
Director of Investor Relations
Michelle Coffey
Global Head of Regulatory Affairs
Donna Skerrett
Chief Medical Officer and Executive Director
Justin Cahill
Chief Financial Officer
Donna Skerrett M.D. Msc
Chief Medical Officer
Catherine Stapledon
R&d Translational Scientist
Jill Forrest
Clinical Operations Lead
Similar companies
Rocket Pharmaceuticals
2 followers
Australian National University Entrepreneurship Club
4 followers
Takeda Pharmaceutical
101 followers
Lundbeck
31 followers
Catalent
13 followers
Cipla
7 followers
Alkem Laboratories Ltd
8 followers
Hikma Pharmaceuticals
5 followers
FXSwede
36 followers
Adani Group
17 followers
Charlie Health
4 followers
Discover companies